Abstract
This clinical trial, together with {1,2}, helped firmly establish the implantable cardioverter defibrillator (ICD) in primary, as well as in secondary, prevention of sudden cardiac death. More recently a subcutaneous version of this device has emerged as a seemingly safer alternative. This Recommendation is of an article referenced in an F1000Prime Report also written by Lars Eckardt, Markus Bettin, Florian Reinke, Benjamin Rath and Julia Köbe.

This publication has 0 references indexed in Scilit: